AZN vs. MRNA
Compare and contrast key facts about AstraZeneca PLC (AZN) and Moderna, Inc. (MRNA).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: AZN or MRNA.
Key characteristics
| AZN | MRNA | |
|---|---|---|
| YTD Return | 15.20% | 12.08% |
| 1Y Return | 5.96% | -15.18% |
| 3Y Return (Ann) | 15.52% | -14.60% |
| 5Y Return (Ann) | 17.70% | 32.68% |
| Sharpe Ratio | 0.28 | -0.33 |
| Daily Std Dev | 22.24% | 49.86% |
| Max Drawdown | -48.94% | -85.65% |
| Current Drawdown | 0.00% | -76.99% |
Fundamentals
| AZN | MRNA | |
|---|---|---|
| Market Cap | $233.06B | $41.34B |
| EPS | $2.02 | -$12.33 |
| PE Ratio | 37.21 | 24.73 |
| PEG Ratio | 0.89 | 0.00 |
| Revenue (TTM) | $47.61B | $6.85B |
| Gross Profit (TTM) | $35.73B | $10.55B |
| EBITDA (TTM) | $15.80B | -$3.62B |
Correlation
The correlation between AZN and MRNA is 0.18, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
AZN vs. MRNA - Performance Comparison
In the year-to-date period, AZN achieves a 15.20% return, which is significantly higher than MRNA's 12.08% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
AZN vs. MRNA - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for AstraZeneca PLC (AZN) and Moderna, Inc. (MRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
AZN vs. MRNA - Dividend Comparison
AZN's dividend yield for the trailing twelve months is around 1.90%, while MRNA has not paid dividends to shareholders.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
AZN AstraZeneca PLC | 1.90% | 2.15% | 2.14% | 2.40% | 2.80% | 2.81% | 3.61% | 3.95% | 5.01% | 4.06% | 3.98% | 4.72% |
MRNA Moderna, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Drawdowns
AZN vs. MRNA - Drawdown Comparison
The maximum AZN drawdown since its inception was -48.94%, smaller than the maximum MRNA drawdown of -85.65%. Use the drawdown chart below to compare losses from any high point for AZN and MRNA. For additional features, visit the drawdowns tool.
Volatility
AZN vs. MRNA - Volatility Comparison
The current volatility for AstraZeneca PLC (AZN) is 5.98%, while Moderna, Inc. (MRNA) has a volatility of 10.81%. This indicates that AZN experiences smaller price fluctuations and is considered to be less risky than MRNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
AZN vs. MRNA - Financials Comparison
This section allows you to compare key financial metrics between AstraZeneca PLC and Moderna, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities